{"nctId":"NCT02652624","briefTitle":"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women","startDateStruct":{"date":"2016-02-19","type":"ACTUAL"},"conditions":["HIV-1 Infection"],"count":472,"armGroups":[{"label":"B/F/TAF","type":"EXPERIMENTAL","interventionNames":["Drug: B/F/TAF"]},{"label":"Baseline Regimen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: E/C/F/TAF","Drug: E/C/F/TDF","Drug: ATV","Drug: RTV","Drug: FTC/TDF"]},{"label":"Extension Phase","type":"EXPERIMENTAL","interventionNames":["Drug: B/F/TAF"]}],"interventions":[{"name":"E/C/F/TAF","otherNames":["Genvoya®"]},{"name":"E/C/F/TDF","otherNames":["Stribild®"]},{"name":"ATV","otherNames":["Reyataz®"]},{"name":"RTV","otherNames":["Norvir®"]},{"name":"FTC/TDF","otherNames":["Truvada®"]},{"name":"B/F/TAF","otherNames":["Biktarvy®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria\n\nMedically stable HIV-1 infected women who meet the following criteria:\n\n* Completion of the Week 48 open-label extension (OLE) visit or any post Week 48 OLE visits in Gilead-sponsored study GS-US-236-0128, or Completion of the Week 96 visit or any post Week 96 visits in Gilead-sponsored study GS-US-292-0109 or completion of the Week 144 visit or any post Week 144 visits in Gilead sponsored studies GS-US-292-0104 or GS-US-292-0111.\n* Currently on a stable antiretroviral regimen consisting of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF continuously for ≥ 12 consecutive weeks preceding the Screening visit\n* Documented plasma HIV-1 RNA levels \\< 50 copies/mL for ≥ 12 weeks preceding the Screening visit. After reaching HIV-1 RNA \\< 50 copies/mL, single values of HIV-1 RNA\n\n  ≥ 50 copies/mL followed by re-suppression to \\< 50 copies/mL is allowed\n* HIV-1 RNA \\<50 copies/mL at screening\n* Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min (≥ 0.83 mL/sec) according to the Cockcroft-Gault formula at the Screening visit\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null},{"groupId":"OG001","value":"95.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":"159.4"},{"groupId":"OG001","value":"26","spread":"170.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":234},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Vulvovaginal candidiasis","Urinary tract infection"]}}}